12,372 trials
Chronic Urticaria
Primary: Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission) — -10.92; -10.61 units on…
Bladder Diseases · Interstitial Cystitis
Primary: Global Response Assessment (GRA) — 74; 61; 61; 75 Participants
Childhood Absence Epilepsy · Juvenile Absence Epilepsy
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 42.2; 55.0 percentage of participants
Chronic Cerebral Ischemia
Primary: Mean Score of Montreal Cognitive Assessment (MoCA) at Visit 5 in Comparison With Reference Score at Visit 0 — 25.72; 23.95; 4.22; 2.17 score on a scale
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of COPD Exacerbations. — 2.0; 3.0 number of exacerbations — p=<0.01
Schizophrenia
Primary: Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score — -12.9; -14.5; -10.3 units on a scale — p=0.182
Critical Illness · Anxiety · Respiratory Failure
Primary: Anxiety Rating Using the 100mm Vertical Visual Analog Scale — 44.4; 43.4; 40.5; 33.1 score on a scale — p=0.30
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -15.0; -14.6; -15.1; -20.5 units on a scale — p=0.972
Alopecia Areata
Primary: Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3 — 5.3; 21.7; 35.2 percentage of participants — p=<0.001
SARS-CoV-2 Infection · COVID-19
Primary: Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination — 5.8; 5.9; 3.8; 3.9 Percentage of participants
Type2 Diabetes · Diabetes Mellitus · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) — -2.03; -0.23 percentage of HbA1c — p=<0.001
Respiratory Syncytial Virus (RSV)
Primary: Geometric Mean Titer (GMT) of Serum Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B)…
Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline in Nasal Polyps Score at Week 24 — -0.50; -2.34 score on a scale — p=<0.0001
Respiratory Syncytial Virus Infections
Primary: Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) — 11910.1; 8593.6 Titer
Breast Carcinoma
Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…